A股異動 | 遼寧成大(600739.SH)漲4.56% 證監會同意子公司成大生物科創板IPO註冊申請
格隆匯9月15日丨遼寧成大(600739.SH)漲4.56%,報25.93元,高見26.65元創近一年新高,總市值397億元。遼寧成大發布公吿,公司擬分拆控股子公司成大生物至上交所科創板上市。成大生物首次公開發行股票並在科創板上市申請已於2020年9月25日通過上交所科創板上市委審核。根據中國證監會9月14日發佈的《關於同意遼寧成大生物股份有限公司首次公開發行股票註冊的批覆》,中國證監會同意成大生物在科創板首次公開發行股票的註冊申請。成大生物將會根據中國證監會及上交所的相關規定及要求開展後續工作。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.